Figure 6. TGF-β1/Smad3 pathway activation mediates ADSC-induced PLOD2 expression in neurons in vitro. (A) Analysis of PLOD2 expression via qRT-PCR in PC12 cells treated with different concentrations of TGF-β1. (B, C) Western blot analysis of PLOD2, P-AKT, AKT, P-Smad3, and Smad2/3 expression in PC12 cells treated with different concentrations of TGF-β1. (D) Analysis of PLOD2 expression via qRT-PCR in PC12 cells treated with LY294002. (E, F) Western blot analysis of P-AKT, AKT, and PLOD2 expression in LY294002-treated PC12 cells. Results presented as mean ± SD and evaluated with one-way ANOVA. *P<0.05, compared to normal and DMSO groups; #P<0.05, compared to MI. LY5: LY294002 (5μM).